Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic and clinical assessment of DC 982 GE in chronic venous disorders
2009-014681-25Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ruscus extract + hesperidin methyl chalcone + ascorbic acid in chronic venous disorder (CVD) and Not applicable (3 arms), sponsored by Pierre Fabre Laboratories. Primary endpoints: Pharmacodynamic dose–response after 28 days and Clinical symptom dose–response after 28 days. Started Sep 2009; status: completed.
02
Drugs
ruscus extract + hesperidin methyl chalcone + ascorbic acid
03
Conditions
chronic venous disorder (CVD)Not applicable
Beyond the preview
Go deeper on 2009-014681-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014681-25.